# Cidara Therapeutics, Inc. — merger [completed]
Source: SEC API (secapi.ai) · situation sit_b149d1dc909be6fba9e2 · retrieved 2026-08-11T16:11:13.492Z

## Overview
Cidara Therapeutics, Inc. is a biopharmaceutical company engaged in the development of biological products.

Merck Sharp & Dohme LLC and its subsidiary Caymus Purchaser, Inc. completed a tender offer to acquire all outstanding common shares of Cidara Therapeutics for $221.50 per share in cash and all outstanding Series A Convertible Voting Preferred Stock for $15,505.00 per share in cash. As of the offer expiration on January 6, 2026, 27,149,333 common shares and 89,956 Series A shares (representing approximately 88.3% of total shares on an as-converted basis) had been validly tendered. Following acceptance of the tendered shares, Purchaser owned sufficient shares to effect the merger under Delaware law without a stockholder vote. The merger closed on January 7, 2026, with Cidara continuing as a wholly owned subsidiary of Merck.

## Terms
- Counterparty: Merck Sharp & Dohme LLC / Caymus Purchaser, Inc. · Consideration: cash · Price/share: $221.5

## Key dates
- Expiry 2026-01-06 · Completed 2026-01-07

## Timeline
- 2026-01-07 · SC 14D9/A (0001193125-26-005515): SC 14D9/A SC 14D9/A
  https://www.sec.gov/Archives/edgar/data/1610618/000119312526005515/d298013dsc14d9a.htm
- 2026-01-07 · 8-K (0001193125-26-005517): 8-K 8-K
  https://www.sec.gov/Archives/edgar/data/1610618/000119312526005517/d57313d8k.htm

## Citations
- 0001193125-26-005515 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526005515
- 0001193125-26-005517 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526005517